Seattle Genetics and Astellas affiliate to co-develop second ADC
US biotech group Seattle Genetics (Nasdaq: SGEN) says it has exercised an option to co-develop a second antibody-drug conjugate (ADC) under the company’s existing ADC collaboration with Agensys, which was acquired for $537 million in 2007 by Japanese drug major Astellas Pharma (Tokyo: 4503).
The ADC, known as ASG-22ME (formerly AGS-22M6E), targets the Nectin-4 antigen, which is expressed on multiple solid tumors. During the first quarter of 2011, Agensys submitted an Investigational New Drug application to the US Food and Drug Administration for a Phase I trial of ASG-22ME. Seattle Genetics and Agensys are also co-developing another ADC known as ASG-5ME, which is currently in Phase I clinical trials for pancreatic and prostate cancer.
Part of deal that could earn Seattle nearly $3 billion
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze